TRABI Stock View

Transgene Biotek Ltd
stock-view-header

icon 0.29 | 3.72
Market Cap ₹( Cr.)
612.98
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
26-Nov-2023
 

The average score for Transgene Biotek Ltd stands at 3 against 2, three months back.

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. It also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
5.12
100 DMA(₹)
4.61
200 DMA(₹)
3.90
52 Weeks Range
2.28     9.50

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required